1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Takeda Continues Recent Gene Therapy Partnering Spree With Poseida Pact

 
• By Joseph Haas

Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.

Takeda Tokyo HQ
Takeda is partnering with biotechs on non-viral delivery of gene therapy

Takeda Pharmaceutical Co. Ltd. unveiled its third gene therapy collaboration in less than two months on 12 October, this time teaming with Poseida Therapeutics, Inc. on a research, development and licensing agreement for six gene therapy candidates, including one for hemophilia A.

The Japanese pharma is paying $45m up front for access to multiple Poseida technology platforms, with a plan to develop...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

More from Advanced Therapies